Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price was up 2.8% during mid-day trading on Monday . The company traded as high as $28.98 and last traded at $28.98, with a volume of 86,814 shares. The stock had previously closed at $28.18.

A number of equities analysts have recently issued reports on TBPH shares. Leerink Swann started coverage on Theravance Biopharma in a research report on Thursday, May 12th. They set an “outperform” rating and a $26.00 price target on the stock. Zacks Investment Research raised Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Tuesday, July 12th. Guggenheim started coverage on Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 price target on the stock. Bank of America Corp. downgraded Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Finally, Evercore ISI started coverage on Theravance Biopharma in a research report on Monday. They set a “buy” rating and a $41.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $32.00.

The stock’s 50-day moving average is $25.30 and its 200-day moving average is $21.36. The stock’s market cap is $1.38 billion.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.01. On average, analysts predict that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current year.

In other Theravance Biopharma news, SVP Brett K. Haumann sold 4,491 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $27.99, for a total value of $125,703.09. Following the completion of the transaction, the senior vice president now owns 188,293 shares of the company’s stock, valued at approximately $5,270,321.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Bradford J. Shafer sold 49,122 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the completion of the transaction, the executive vice president now directly owns 241,686 shares of the company’s stock, valued at approximately $6,636,697.56. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.